Assignee
VICORE PHARMA AB
SE·11 granted patents·23 pending applications·28 citations·filing 2003–2025
Top patents by PatentIndex Score
34 records- 0193US11819494B2Treatment of idiopathic pulmonary fibrosisVICORE PHARMA AB·Filed 2022·Granted Nov 21, 2023·5 cites·19 claims
- 0293US11123329B1Use of angiotensin II type 2 receptor agonistVICORE PHARMA AB·Filed 2020·Granted Sep 21, 2021·5 cites·14 claims
- 0390US12128029B2Treatment of idiopathic pulmonary fibrosisVICORE PHARMA AB·Filed 2023·Granted Oct 29, 2024·1 cites·25 claims
- 0490US11654115B2Delayed release composition for peroral administrationVICORE PHARMA AB·Filed 2022·Granted May 23, 2023·5 cites·23 claims
- 0588US11844868B2Dry powder composition for peroral administrationVICORE PHARMA AB·Filed 2022·Granted Dec 19, 2023·5 cites·28 claims
- 0686US12121614B2Delayed release composition for peroral administrationVICORE PHARMA AB·Filed 2023·Granted Oct 22, 2024·1 cites·16 claims
- 0786US2026069572A1Treatment of idiopathic pulmonary fibrosisVICORE PHARMA AB·Filed 2025·Application pending·0 cites
- 0884US12213961B2Treatment of idiopathic pulmonary fibrosisVICORE PHARMA AB·Filed 2023·Granted Feb 4, 2025·0 cites·27 claims
- 0983US2025177355A1Treatment of idiopathic pulmonary fibrosisVICORE PHARMA AB·Filed 2024·Application pending·0 cites
- 1080US2026007608A1New delayed release composition for peroral administrationVICORE PHARMA AB·Filed 2025·Application pending·0 cites
- 1179US12441718B2Selective angiotensin II compoundsVICORE PHARMA AB·Filed 2024·Granted Oct 14, 2025·0 cites·3 claims
- 1277US2025235408A1New delayed release composition for peroral administrationVICORE PHARMA AB·Filed 2024·Application pending·0 cites
- 1374US2026028333A1New compoundsVICORE PHARMA AB·Filed 2025·Application pending·0 cites
- 1471US7652054B2Tricyclic compounds useful as angiotensin II agonistsVICORE PHARMA AB·Filed 2003·Granted Jan 26, 2010·6 cites·22 claims
- 1562US2024262813A1New selective angiotensin ii compoundsVICORE PHARMA AB·Filed 2022·Application pending·0 cites
- 1662US2021386712A1New use of angiotensin ii type 2 receptor agonistVICORE PHARMA AB·Filed 2021·Application pending·0 cites
- 1761US12435072B2CompoundsVICORE PHARMA AB·Filed 2020·Granted Oct 7, 2025·0 cites·18 claims
- 1860US2024207230A1Method of treating a patient diagnosed with an interstitial lung diseaseVICORE PHARMA AB·Filed 2023·Application pending·0 cites
- 1958US2024207232A1Method of treating a patient diagnosed with an interstitial lung diseaseVICORE PHARMA AB·Filed 2023·Application pending·0 cites
- 2057US2024174657A1Selective angiotensin ii receptor ligandsVICORE PHARMA AB·Filed 2022·Application pending·0 cites
- 2156US2024207231A1Method of treating a patient diagnosed with an interstitial lung diseaseVICORE PHARMA AB·Filed 2023·Application pending·0 cites
- 2255US2023183223A1Process for the synthesis of n-butyloxycarbonyl-3-(4-imidazol-1- ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamideVICORE PHARMA AB·Filed 2021·Application pending·0 cites
- 2355US2024197685A1Selective angiotensin ii receptor ligandsVICORE PHARMA AB·Filed 2022·Application pending·0 cites
- 2455US2024182461A1Selective angiotensin ii receptor ligandsVICORE PHARMA AB·Filed 2022·Application pending·0 cites
- 2554US2022233480A1Use of angiotensin ii type 2 receptor agonistVICORE PHARMA AB·Filed 2022·Application pending·0 cites
- 2653US2023348444A1Novel compounds for use in the treatment of diseases associated with angiotensin iiVICORE PHARMA AB·Filed 2021·Application pending·0 cites
- 2751US2023114153A1Imidazolyl thiopehene sulfonyl carbamates for use in the treatment of diseases associated with angiotensin iiVICORE PHARMA AB·Filed 2021·Application pending·0 cites
- 2851US2015209332A1Use of Angiotensin II AgonistsVICORE PHARMA AB·Filed 2014·Application pending·0 cites
- 2951US2023149362A1New capsule composition for peroral administrationVICORE PHARMA AB·Filed 2021·Application pending·0 cites
- 3051US2023159467A1Novel compounds useful in the treatment and/or prevention of a disease, disorder or condition associated with angiotensin iiVICORE PHARMA AB·Filed 2021·Application pending·0 cites
- 3147US2021401807A1New composition comprising amorphous nanoporous silica particlesVICORE PHARMA AB·Filed 2019·Application pending·0 cites
- 3236US2017266164A1New methods and usesVICORE PHARMA AB·Filed 2015·Application pending·0 cites
- 3335US8357710B2Bicyclic angiotensin II agonistsVICORE PHARMA AB·Filed 2006·Granted Jan 22, 2013·0 cites·19 claims
- 3429US2018078529A1Angiotensin ii receptor agonist for treating pulmonary fibrosisVICORE PHARMA AB·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when VICORE PHARMA AB files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →